This website contains information based on the Summary of Product Characteristics (SPC), as approved by the European Commission on Jivi (damoctog alfa pegol), Kovaltry (octocog alfa) and Kogenate FS (octocog alfa). It is intended to provide information to an international audience. In countries outside the EU, the local Product Information applies.
Omar* is a busy 14-year-old who is eager to keep up with his friends and be more independent. Right now, he wants to be allowed to ride his bike to school rather than have his parents drive him there. But his parents aren’t so sure. They worry about accidents, bleeds, and a possible impact on his joints.
For his parents to feel confident about giving Omar more independence, Omar needs a treatment that offers him powerful protection.
For young patients like Omar, Jivi delivers:1,2
Joint protection that lasts†
Powerful protection from bleeds
As demonstrated in adolescents in PROTECT VIII
See your young patients through the adventures of adolescence with Jivi
* Patient names and descriptions are fictitious.
† The median (Q1; Q3, range) total time treated with Jivi (during both main and extension) was 4.04 (3.08; 5.05,1.3–6.2) years.1
‡ Ten out of 12 patients reported target joints at enrolment. During the last 12 months of the extension, all target joints present at pre-study (as reported by the investigator) or that developed during the study (3 bleeds into the same joint in 6 months), were resolved (≤2 spontaneous bleeds/year).1
§ n=12. Prior to study entry, all patients included in this analysis were on regular FVIII prophylaxis treatment, except one (on-demand FVIII treatment).1
ABR, annualized bleeding rate; Q, quartile.
References:
1. Reference to be updated: Ducore J et al. Efficacy and safety of damoctocog alfa pegol is sustained for up to ≥6 years of observation in patients aged 12-<18 years at enrolment into PROTECT VIII. Poster presented at Hemostasis & Thrombosis Research Society 2021 Scientific Symposium Virtual Conference. March 10-12, 2021.
Raul* has moderate hemophilia and has previously only used on-demand treatment. Now that he is in his teens, Raul has started to become more active, and wants to be able to join his friends in playing football.
Although Raul has a moderate rather than severe form of hemophilia, his doctor has advised that in order to stay protected enough to safely participate in this new level of activity, Raul will still need to step up to prophylaxis.
Jivi’s powerful protection from bleeds and 1x weekly dosing option helps ease your mild-to-moderate patients like Raul into prophylaxis.1,2
Ease your mild-to-moderate patients into prophylaxis with Jivi’s powerful protection
* Patient names and descriptions are fictitious.
† Please refer to local prescribing information. Not all patients are candidates for 1x weekly dosing.
‡ Among previously treated males (n=22) aged 12–65 years with severe hemophilia A (FVIII <1%).1
§ Based on head-to-head studies comparing the pharmacokinetic profiles of Jivi vs. rFVIII-Fc and Jivi vs. rurioctocog alfa pegol.
Eligible patients in both studies were men aged 18–65 years with severe hemophilia A (FVIII <1 IU/dL) previously treated with any FVIII product for ≥150 exposure days (EDs).2,3
References:
1. Miesbach W et al. Haemophilia. 2020; 26(3): 467-477.
2. Reding MT et al. Haemophilia 2021; 27(3): e347-e356.
3. Shah A et al. Ann Hematol 2019; 989(9): 2035-2044.
4. Solms A et al. Ann Hematol 2020; 99: 2689-2698.
Max* is excited about starting college and is all set to enter this new whole phase in his life. Between all the studying and socialising he is going to be doing, Max knows that he is going to be much busier at college.
To help Max thrive at college, he needs a treatment with a strong PK profile that can offer him more time to be active.
For patients like Max, Jivi delivers1-4
Jivi gives patients more time to do what matters to them
* Patient names and descriptions are fictitious.
† Based on head-to-head studies of Jivi vs. rFVIII-Fc and Jivi vs. rurioctocog alfa pegol, which compared the median time to achieve FVIII thresholds of 1,3,5 and 10%.1
References:
1. Shah A et al. Ann Hematol 2019: 98(9): 2035–2044.
2. Solms A et al. Ann Hematol 2019; 99: 2689–2698.
3. Reding MT et al. Hemophilia 2020; 26: e201–e204
Bob* graduated a couple of years back and, following a period spent working in part-time intermediate jobs, he has now landed his dream job in his chosen career. This means relocating, working longer hours and generally adapting his life to this exciting new set of circumstances.
To help Bob succeed in this transition, he needs a treatment that offers fewer infusions.
For patients like Bob, who want to achieve more with fewer infusions, Jivi delivers powerful protection1 with higher and more sustained FVIII levels2,3†
With Jivi, your patients like Bob can focus on life, not treatment
* Patient names and descriptions are fictitious.
† In head-to-head studies comparing the pharmacokinetic profiles of Jivi vs. rFVIII-Fc and Jivi vs. rurioctocog alfa pegol, Jivi demonstrated significantly higher AUC, significantly slower clearance, and significantly longer half-life.2,3
‡ Please refer to local prescribing information. Not all patients are candidates for 1x weekly dosing.
§ n=23. During the last 12 months of the extension.
References:
1. Reding MT et al. Haemophilia 2021; 27(3): e347-e356.
2. Shah A et al. Ann Hematol 2019; 989(9): 2035-2044.
3. Solms A et al. Ann Hematol 2020; 99: 2689-2698.
Gary* has a young family – he loves playing with his kids but he’s starting to experience joint pain, so it can be tough.
Gary wants to be having fun with his kids every second they’re together, but he needs to look after himself and his joints too. It’s important to him that he can make the most out of the time they have during these early years.
For patients like Gary, who are experiencing joint pain, Jivi delivers powerful protection from joint damage:
Strengthen your patients’ futures with Jivi
* Patient names and descriptions are fictitious.
† Numbers of historic target joints were recorded at study entry (as judged by the investigator), new target joints that developed on study (ISTH definition: ≥3 spontaneous bleeds within 6 months) and resolved target joints (ISTH definition: a recorded target joint with ≤2 spontaneous bleeds during last 12 months) were analyzed in patients known to have received prophylaxis before study entry and who continued on prophylaxis into the extension.1 The majority of patients (72%) continuing on prophylaxis into the extension had target joints at baseline.1
‡ 122 target joints (113 historic and 9 new) were recorded in 62 patients, 111 of which were resolved.2
§ At extension completion, patients received Jivi for a median (range) total time of 3.9 (0.8–7.0) years with 223 (23–698) exposure days.2
¶ n=82 (this includes 3 patients who switched to prophylaxis at the start of the extension from on-demand regimen in the pre- and main studies).2
ISTH, International Society on Thrombosis and Haemostasis; PK, pharmacokinetic.
References:
1. Reding MT et al. Haemophilia 2021; 27(3): e347-e356.
2. Reding MT et al. Haemophilia 2020; 26: e201–e204.
Jason* has always felt wary about the prospect of routine prophylaxis, which is why he has stuck with on-demand treatment. But this treatment approach has led to him experiencing many more bleeds, including joint bleeds, along with the ensuing pain and joint damage.
Now in his 40s, the number of bleeds and level of joint damage is becoming unbearable. And because Jason has to infuse every time he bleeds, his doctor has pointed out that if he switched to prophylaxis then he would dramatically lower his bleed rate without actually having to infuse that much more often.
Jivi’s powerful protection from bleeds and 1x weekly dosing option helps ease your on-demand patients, like Jason, into prophylaxis.1,2 †
In PROTECT VIII, patients who switched from on-demand to Jivi prophylaxis demonstrated
an almost 100% reduction in bleeds across all regimens.1
For patients like Jason, Jivi prophylaxis is a small step that delivers powerful protection
* Patient names and descriptions are fictitious.
† Please refer to local prescribing information. Not all patients are candidates for 1x weekly dosing.
ABR, annualized bleed rate.
References:
1. Reding MT et al. Haemophilia 2021; 27(3): e347-e356.
Because of advances in treatment, people with hemophilia are now living longer and fuller lives than ever before. Carlos* is a proud member of this new generation of people with hemophilia. He is in his 50s, which – like others in this new generation of patients – now also puts him at risk from age-related comorbidities.
Carlos already has hypertension, as well as joint issues relating to hemophilia. So, his doctor needs to consider his treatment carefully. Carlos needs powerful protection for his joints, but it is important that his treatment does not exacerbate his comorbidities.
For patients with age-related comorbidities like Carlos, Jivi provides powerful protection with the reassurance of no observed cardiovascular events:1
Give your patients powerful protection with the reassurance of no associated thrombotic risk
* Patient names and descriptions are fictitious.
† Range: 0.0–12.0
‡ Range: 0.0–4.1
References:
1. Reference to be updated: Reding MT et al. Efficacy and safety of BAY 94-9027 prophylaxis in patients ≥ 40 years with severe hemophilia A and comorbidities from the PROTECT VIII study.